Efficacy and Safety of Intravenous Treatment of Tuberculosis

Tuberculosis, Pulmonary Clinical Trial

Official title:

Open-label, Randomized, Multicenter, Controlled, Parallel, Comparative Study of Efficacy and Safety of Treatment of Tuberculosis With Isoniazid, Rifampicin, Ethambutol for Intravenous Infusion in Comparison With Oral Forms While the Intensive Phase of Treatment for Patients With Widespread Destructive Pulmonary Tuberculosis With Bacterial Excretion.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04150367
• Other study ID #: Invent-1
• Status: Terminated
• Start date: March 3, 2017
• Est. completion date: July 14, 2018

Study information

• Verified date: November 2019
• Source: Yuria-Pharm
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This Open-label, Randomized, Multicenter, Controlled, Parallel, Comparative Study will compare the efficacy and safety of intravenous treatment with Isoniazid, Rifampicin, Ethambutol first two months of intensive phase of tuberculosis treatment and the treatment with the oral forms of Isoniazid, Rifampicin, Ethambutol first two months of intensive phase of tuberculosis treatment for Patients With Widespread Destructive Pulmonary Tuberculosis With Bacterial Excretion.

Description:

There are two groups of patients with first diagnosed widespread destructive pulmonary tuberculosis with bacterial excretion. The first group receives intravenous treatment with Isoniazid, Rifampicin, Ethambutol first two months of intensive phase of tuberculosis treatment. The second group gets oral forms of Isoniazid, Rifampicin, Ethambutol first two months of intensive phase of Tuberculosis treatment. Then both groups receive oral treatment of tuberculosis according to the known scheme.

Up to 318 participants will be randomized into this study, with 159 participants being randomized to the control arm and 159 participants being randomized to the experimental arm. It Supposed that not less than 254 participants will finish the study (about 127 participants in each arm) and their results will be included in the statistical analysis.

While the intensive phase participants of both arms will be hospitalized in the Tuberculosis Dispensary.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 166
• Est. completion date: July 14, 2018
• Est. primary completion date: July 14, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. men and women;

2. The age of 18 - 65 years inclusive;

3. Patients diagnosed with: first diagnosed pulmonary tuberculosis;

4. Patients with at least one positive result of a microbiological study of the sputum on the Mycobacterium tuberculosis (during the screening, the results of a microbiological sputum examination on an Mycobacterium tuberculosis up to 7 days old can be used);

5. Patients with radiographically and optionally CT confirmed cavity / cavities of destruction in the lungs, as well as a widespread tuberculosis process (occupying at least 2 segments of the lungs) (during the screening, the results of X-ray examination of the chest up to 7 days old can be used );

6. For women with reproductive potential - negative result of urine test for pregnancy and consent to use a reliable method of contraception before the end of the study;

7. Provided informed written consent of the patient to participate in the study;

8. The patient's ability to adequately cooperate in the research process;

9. Patients with negative analysis of GenXpert MBT / RIF (at the time of screening, analysis results not older than 7 days may be used);

10. Oral consent of the patient to stop using alcohol during the study period.

Exclusion Criteria:

1. Patients who, according to the results of a sputum test using the GenXpert MBT / RIF method, are determined to be resistant to rifampicin.

2. Pregnancy, lactation;

3. Epilepsy and other diseases, which are accompanied by a tendency to convulsive seizures;

4. Severe psychosis;

5. Poliomyelitis (including in the anamnesis);

6. Diseases of the cardiovascular system, respiratory system, diabetes mellitus, impaired liver function, kidney, thyroid gland, vision, the presence of concomitant diseases or acute conditions, which, according to the researcher, do not allow the patient to participate in this study;

7. HIV infection;

8. Intolerance (including history) of any of the drugs studied;

9. Participation in any other clinical trial at the time of inclusion in this study and for the last 30 days before the date of screening.

Related Conditions & MeSH terms

• Tuberculosis
• Tuberculosis, Pulmonary

Intervention

Drug:
• Isoniazid
Solution for injections, 100 mg/ml, 5 ml. Participants will get the dosage according to the instruction for use.
• Rifampicin
Participants will get the dosage according to the instruction for use.
• Ethambutol
Participants will get the dosage according to the instruction for use.
• Rifampicin
Participants will get the dosage according to the instruction for use.
• Isoniazid
. Participants will get the dosage according to the instruction for use.
• Ethambutol
Participants will get the dosage according to the instruction for use.

Locations

Country	Name	City	State
Ukraine	Regional Clinical Antituberculosis Dispensary	Chernivtsi
Ukraine	Regional phthisiopulmonary center	Ivano-Frankivs'k
Ukraine	Regional Antituberculosis Dispensary ?1	Kharkiv
Ukraine	Regional Antituberculosis Dispensary	Kherson
Ukraine	National Yanovsky's Institute of Phthisiology and Pulmonology	Kyiv
Ukraine	Lviv Regional Phthisiopneumological Clinical Treatment and Diagnostic Center	L'viv
Ukraine	Regional territorial medical anti-tuberculosis association	Luts'k
Ukraine	Regional Clinical Antituberculosis Dispensary	Sumy
Ukraine	Ternopil Regional TB Dispensary	Ternopil'

Sponsors (1)

Lead Sponsor	Collaborator
Yuria-Pharm

Country where clinical trial is conducted

Ukraine, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Percentage ratio of severe adverse events.	All kinds of adverse events.	From 1 week till 7 months after the start of treatment.
Other	Comparative cost of treatment of the main disease and complications at 6 months after the start of the treatment.	Comparative cost of treatment of the main disease and complications based on the average cost of all medical services for the medical institutions participating in the study at 6 months after the start of treatment.	6 months after the start of treatment/
Other	Comparative cost of treatment of the main disease and complications at 12 months after the start of the treatment.	Comparative cost of treatment of the main disease and complications based on the average cost of all medical services for the medical institutions participating in the study at 12 months after the start of treatment.	12 months after the start of treatment
Other	Comparative cost of treatment of the main disease and complications at 18 months after the start of the treatment.	Comparative cost of treatment of the main disease and complications based on the average cost of all medical services for the medical institutions participating in the study at 18 months after the start of treatment.	18 months after the start of treatment
Primary	Percentage of patients with negative results of sputum analysis on Mycobacterium tuberculosis .	Percentage of patients with negative results of sputum analysis on Mycobacterium tuberculosis in the main and control groups.	?he end of the 1st month from the start of treatment (after taking 30 doses of each drug by the patient)
Secondary	Time until the negative result of the Mycobacterium tuberculosis tests is obtained.	Time until the negative result of sputum Mycobacterium tuberculosis tests is obtained for each patient.	2 weeks - 3 months
Secondary	Combined percentage ratio of patients with negative results of Mycobacterium tuberculosis analysis and clinical improvement.	Combined percentage ratio of patients who have negative results of sputum analysis on Mycobacterium tuberculosis and clinical improvement at the same time.	2 months after the start of treatment (after taking the patient 60 doses of each preparation of the intensive phase).
Secondary	Combined percentage of patients with no response to treatment in 12 months.	Combined percentage ratio of patients with no response to treatment in 12 months.	12 months after the start of treatment (13 months after initiation of treatment for patients who still have the positive results of the sputum analysis on Mycobacterium tuberculosis after taking 60 doses of each preparation of the intensive phase).
Secondary	Combined percentage ratio of patients with no response to treatment in 18 months.	Combined percentage ratio of patients with no response to treatment in 18 months.	18 months after the start of treatment (19 months after initiation of treatment for patients who still have the positive results of the sputum analysis on Mycobacterium tuberculosis after taking 60 doses of each preparation of the intensive phase).
Secondary	Combined percentage ratio of patients with relapse of active tuberculosis in 18 months.	Combined percentage ratio of patients with relapse of active tuberculosis in 18 months.	18 months after the start of treatment (19 months after initiation of treatment for patients who still have the positive results of the sputum analysis on Mycobacterium tuberculosis after taking 60 doses of each preparation of the intensive phase).
Secondary	Combined percentage ratio of patients with death due to active tuberculosis in 18 months.	Combined percentage ratio of patients with death due to active tuberculosis in 18 months.	18 months after the start of treatment (19 months after initiation of treatment for patients who still have the positive results of the sputum analysis on Mycobacterium tuberculosis after taking 60 doses of each preparation of the intensive phase).
Secondary	Combined percentage ratio of patients with relapse of active tuberculosis in 12 months.	Combined percentage ratio of patients with relapse of active tuberculosis in 12 months.	12 months after the start of treatment (13 months after initiation of treatment for patients who still have the positive results of the sputum analysis on Mycobacterium tuberculosis after taking 60 doses of each preparation of the intensive phase).
Secondary	Combined percentage ratio of patients with death due to active tuberculosis in 12 months.	Combined percentage ratio of patients with death due to active tuberculosis in 12 months.	12 months after the start of treatment (13 months after initiation of treatment for patients who still have the positive results of the sputum analysis on Mycobacterium tuberculosis after taking 60 doses of each preparation of the intensive phase).